Premium
Small‐diameter titanium G rade IV and titanium–zirconium implants in edentulous mandibles: three‐year results from a double‐blind, randomized controlled trial
Author(s) -
Quirynen Marc,
AlNawas Bilal,
Meijer Henny J.A.,
Razavi Amir,
Reichert Torsten E.,
Schimmel Martin,
Storelli Stefano,
Romeo Eugenio
Publication year - 2015
Publication title -
clinical oral implants research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.407
H-Index - 161
eISSN - 1600-0501
pISSN - 0905-7161
DOI - 10.1111/clr.12367
Subject(s) - medicine , dentistry , implant , soft tissue , titanium , randomized controlled trial , radiography , survival rate , orthodontics , surgery , materials science , metallurgy
Objective The aim of this study was to compare crestal bone‐level changes, soft tissue parameters and implant success and survival between small‐diameter implants made of titanium/zirconium ( T i Z r) alloy or of G rade IV titanium ( T i) in edentulous mandibles restored with removable overdentures. Materials and Methods This was a randomized, controlled, double‐blind, split‐mouth multicenter clinical trial. Patients with edentulous mandibles received two Straumann bone‐level implants (diameter 3.3 mm), one of T i G rade IV (control) and one of T i Z r (test), in the interforaminal region. Implants were loaded after 6–8 weeks and removable Locator‐retained overdentures were placed within 2 weeks of loading. Modified plaque and sulcus bleeding indices, radiographic bone level, and implant survival and success were evaluated up to 36 months. Results Of 91 treated patients, 75 completed the three‐year follow‐up. Three implants were lost (two control and one test implant). The survival rates were 98.7% and 97.3%, and the mean marginal bone level change was −0.78 ± 0.75 and −0.60 ± 0.71 mm for T i Z r and T i G rade IV implants. Most patients had a plaque score of 0 or 1 (54% for test and 51.7% for control), and a sulcus bleeding score of 0 (46.1% for test and 44.9% for control). No significant differences were found between the two implant types for bone‐level change, soft tissue parameters, survival and success. Conclusions After 36 months, similar outcomes were found between T i G rade IV and T i Z r implants. The results confirm that the results seen at 12 months continue over time.